Jazz Pharmaceuticals, Inc. (JAZZ) Stock Price

JAZZStock

$244.54+93.88%52W

Market Cap$15.87B

P/E19.93x

PEG Ratio0.96

Div yield—

Beta0.36

JAZZ Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)28.75%

Price vs S&P 500 (4W)-4.34%

PEG Ratio0.96

VGM Score57.58

P/E Ratio (Annual)19.93x

P/CF (Annual)11.77x

Book Value / Share (Quarterly)$74.10

P/TBV (Annual)6.28x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)5.26%

Cash Flow / Share (Quarterly)$21.42

Price vs S&P 500 (YTD)31.03%

Gross Margin (TTM)88.42%

Net Profit Margin (TTM)20.45%

EPS (TTM)$14.63

10-Day Avg Trading Volume1.28M

EPS Excl Extra (TTM)$14.63

Revenue Growth (5Y)12.54%

EPS (Annual)$-5.84

ROI (Annual)-3.68%

Gross Margin (Annual)88.21%

Net Profit Margin (5Y Avg)-0.11%

Cash / Share (Quarterly)$33.95

P/E Basic Excl Extra (TTM)16.97x

Revenue Growth QoQ (YoY)15.55%

EPS Growth (5Y)-1.36%

P/E Normalized (Annual)19.93x

ROA (Last FY)-3.05%

Revenue Growth TTM (YoY)12.59%

EBITD / Share (TTM)$24.44

ROE (5Y Avg)0.19%

Operating Margin (TTM)19.49%

Cash Flow / Share (Annual)$18.65

P/B Ratio3.32x

P/B Ratio (Quarterly)3.15x

Net Income / Employee (Annual)$-123,200

EV / Revenue (TTM)4.06x

Net Interest Coverage (TTM)-2.18x

ROA (TTM)8.19%

EPS Growth QoQ (YoY)7.21%

EV / EBITDA (TTM)11.85x

EPS Incl Extra (Annual)$-5.84

Current Ratio (Annual)1.86x

Quick Ratio (Quarterly)1.49x

3-Month Avg Trading Volume0.92M

52-Week Price Return93.88%

EV / Free Cash Flow (Annual)16.31x

P/E Incl Extra (TTM)16.97x

Revenue / Employee (TTM)$1,592,100

Tangible BV / Share (Quarterly)$11.92

P/S Ratio (Annual)3.74x

Asset Turnover (Annual)0.37x

52-Week High$266.38

Operating Margin (5Y Avg)5.27%

EPS Excl Extra (Annual)$-5.84

CapEx CAGR (5Y)-11.17%

Tangible BV CAGR (5Y)42.31%

26-Week Price Return40.68%

Quick Ratio (Annual)1.60x

13-Week Price Return3.89%

Total Debt / Equity (Annual)1.24x

Current Ratio (Quarterly)1.78x

Enterprise Value$18.70B

Revenue / Share Growth (5Y)10.84%

Asset Turnover (TTM)0.40x

Book Value / Share Growth (5Y)1.47%

Revenue / Employee (Annual)$1,476,700

Inventory Turnover (Annual)1.12x

Pretax Margin (Annual)-14.71%

Cash / Share (Annual)$39.75

3-Month Return Std Dev29.25%

Gross Margin (5Y Avg)87.38%

Net Income / Employee (TTM)$325,500

EBITDA CAGR (5Y)-18.72%

EBITDA Interim CAGR (5Y)42.61%

ROE (Last FY)-8.25%

Net Interest Coverage (Annual)5.30x

EPS Basic Excl Extra (Annual)$-5.84

P/FCF (TTM)11.50x

Receivables Turnover (TTM)5.77x

EV / Free Cash Flow (TTM)13.47x

Total Debt / Equity (Quarterly)0.91x

EPS Incl Extra (TTM)$14.63

Receivables Turnover (Annual)5.52x

ROI (TTM)9.89%

P/S Ratio (TTM)3.47x

Pretax Margin (5Y Avg)-1.84%

Revenue / Share (Annual)$69.98

Tangible BV / Share (Annual)$26.16

Forward P/E10.14x

Free OCF CAGR (5Y)17.11%

Price vs S&P 500 (52W)75.32%

P/E Ratio (TTM)16.97x

EPS Growth TTM (YoY)-98.57%

Year-to-Date Return43.85%

5-Day Price Return-3.90%

EPS Normalized (Annual)$-5.84

ROA (5Y Avg)0.10%

Net Profit Margin (Annual)-8.35%

Month-to-Date Return-3.29%

Cash Flow / Share (TTM)$10.05

EBITD / Share (Annual)$3.68

Operating Margin (Annual)-10.08%

LT Debt / Equity (Annual)1.00x

P/CF (TTM)9.61x

ROI (5Y Avg)0.07%

P/E Excl Extra (TTM)16.97x

LT Debt / Equity (Quarterly)0.69x

EPS Basic Excl Extra (TTM)$14.63

P/TBV (Quarterly)19.60x

P/B Ratio (Annual)2.39x

Inventory Turnover (TTM)1.12x

Pretax Margin (TTM)15.82%

Book Value / Share (Annual)$70.30

Price vs S&P 500 (13W)1.94%

Net Margin Growth (5Y)-10.67%

Beta0.36x

P/FCF (Annual)13.93x

Revenue / Share (TTM)$66.30

ROE (TTM)21.37%

52-Week Low$123.88

vGradeB

gGradeC

mGradeB

vgmGradeC

JAZZ Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 3, 2026	$6.18	$5.71	-7.54%(-$0.47)
Q1 2026	May 5, 2026	$4.66	$6.34	+36.18%(+$1.68)
Q4 2025	Feb 24, 2026	$6.51	$6.64	+2.05%(+$0.13)
Q3 2025	Nov 5, 2025	$5.85	$8.13	+38.97%(+$2.28)
Q2 2025	Aug 5, 2025	-$6.25	-$8.25	-32.07%(-$2.00)

JAZZ Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.25

4.24

4.20

4.19

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	C	C	B	$17.54

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical company with approved treatments in neuroscience and oncology. Its portfolio of nine drugs includes leading franchises such as Xyrem/Xywav for narcolepsy, Epidiolex for severe epilepsy (acquired in 2021 from GW Pharmaceuticals), and oncology medications including Zepzelca, Rylaze, and Vyxeos. The company focuses on high-unmet-need therapeutic areas with limited competitive options.